Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο: https://hdl.handle.net/10442/19188
Export to:   BibTeX  | EndNote  | RIS
Εξειδίκευση τύπου : Άρθρο σε επιστημονικό περιοδικό
Τίτλος: AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors
Δημιουργός/Συγγραφέας: Gkekas, Ioannis
Katsamakas, Sotirios
Mylonas, Stelios
Fotopoulou, Theano
[EL] Μαγουλάς, Γιώργος[EN] Magoulas, Georgesemantics logo
Tenchiu, Alia Christina
Dimitriou, Marios
Axenopoulos, Apostolos
Rossopoulou, Nafsika
Kostova, Simona
Wanker, Erich E
[EL] Κατσίλα, Θεοδώρα[EN] Katsila, Theodorasemantics logo
Papahatjis, Demetris
Gorgoulis, Vassilis G
[EL] Κουφάκη, Μαρία[EN] Koufaki, Mariasemantics logo
Karakasiliotis, Ioannis
[EL] Καλογεροπούλου, Θεοδώρα[EN] Calogeropoulou, Theodorasemantics logo
Daras, Petros
Petrakis, Spyros
Ημερομηνία: 2024-11-13
Γλώσσα: Αγγλικά
ISSN: 1549-9596
1549-960X
DOI: 10.1021/acs.jcim.4c01110
Άλλο: 39535926
Περίληψη: Coronavirus disease 2019 (COVID-19) is caused by a new, highly pathogenic severe-acute-respiratory syndrome coronavirus 2 (SARS-CoV-2) that infects human cells through its transmembrane spike (S) glycoprotein. The receptor-binding domain (RBD) of the S protein interacts with the angiotensin-converting enzyme II (ACE2) receptor of the host cells. Therefore, pharmacological targeting of this interaction might prevent infection or spread of the virus. Here, we performed a virtual screening to identify small molecules that block S-ACE2 interaction. Large compound libraries were filtered for drug-like properties, promiscuity and protein-protein interaction-targeting ability based on their ADME-Tox descriptors and also to exclude pan-assay interfering compounds. A properly designed AI-based virtual screening pipeline was applied to the remaining compounds, comprising approximately 10% of the starting data sets, searching for molecules that could bind to the RBD of the S protein. All molecules were sorted according to their screening score, grouped based on their structure and postfiltered for possible interaction patterns with the ACE2 receptor, yielding 31 hits. These hit molecules were further tested for their inhibitory effect on Spike RBD/ACE2 (19-615) interaction. Six compounds inhibited the S-ACE2 interaction in a dose-dependent manner while two of them also prevented infection of human cells from a pseudotyped virus whose entry is mediated by the S protein of SARS-CoV-2. Of the two compounds, the benzimidazole derivative CKP-22 protected Vero E6 cells from infection with SARS-CoV-2, as well. Subsequent, hit-to-lead optimization of CKP-22 was effected through the synthesis of 29 new derivatives of which compound CKP-25 suppressed the Spike RBD/ACE2 (19-615) interaction, reduced the cytopathic effect of SARS-CoV-2 in Vero E6 cells (IC50 = 3.5 μM) and reduced the viral load in cell culture supernatants. Early in vitro ADME-Tox studies showed that CKP-25 does not possess biodegradation or liver metabolism issues, while isozyme-specific CYP450 experiments revealed that CKP-25 was a weak inhibitor of the CYP450 system. Moreover, CKP-25 does not elicit mutagenic effect on Escherichia coli WP2 uvrA strain. Thus, CKP-25 is considered a lead compound against COVID-19 infection.
Τίτλος πηγής δημοσίευσης: Journal of chemical information and modeling
Θεματική Κατηγορία: [EL] Θεραπευτική. Φαρμακολογία[EN] Therapeutics.Pharmacologysemantics logo
[EL] Ιολογία[EN] Virologysemantics logo
[EL] Επιδημίες. Επιδημιολογία[EN] Epidemics. Epidemiologysemantics logo
[EL] Φασματοσκοπία[EN] Spectroscopysemantics logo
[EL] Δομική Βιολογία[EN] Structural Biologysemantics logo
Λέξεις-Κλειδιά: COVID-19
SARS-CoV-2
infectious diseases
peptides and proteins
reaction products
EU Grant: OPENSCREEN-GR: An Open-Access Research Infrastructure of Chemical Biology and Target-Based Screening Technologies for Human and Animal Health Agriculture and the Environment” “(2018–2020)
National Public Investment Program
Operational Program Competitiveness, Entrepreneurship and Innovation
EU Grant identifier: 5002691
2020ΣΕ01300001
5150060
Κάτοχος πνευματικών δικαιωμάτων: © 2024 The Authors. Published by American Chemical Society
Ηλεκτρονική διεύθυνση στον εκδότη (link): https://doi.org/10.1021/acs.jcim.4c01110
Εμφανίζεται στις συλλογές:Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο

Αρχεία σε αυτό το τεκμήριο:
Αρχείο Περιγραφή ΣελίδεςΜέγεθοςΜορφότυποςΈκδοσηΆδεια
Gkekas et al_2024_acs.jcim.4c01110.pdfOpen access article6.75 MBAdobe PDFΔημοσιευμένη/του ΕκδότηccbyΔείτε/ανοίξτε